Diabete : Hypoglykemie, Holleman F., Schmitt H., Rottiers R., Rees A., Symanowski S., Anderson J.H. : Reduced frequency of severe hypoglycaemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. (BD Medical/Diabetes Care)
 


artikel suikerziekte



  • coma

  • mmol l

  • glucose

  • diabetes





  • coma, mmol l, glucose, diabetes

      
    Home > Sitemap > Informatie centrum > Medische referenties : Hypoglykemie > Holleman F., Schmitt H., Rottiers R., Rees A., Symanowski S., Anderson J.H. : Reduced frequency of severe hypoglycaemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group.
    Holleman F., Schmitt H., Rottiers R., Rees A., Symanowski S., Anderson J.H. : Reduced frequency of severe hypoglycaemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group.  Back
    Department of Internal Medicine, Diakonessenhuis, Utrecht, The Netherlands.

    Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group.
    OBJECTIVE: Several studies have suggested that use of the short-acting insulin analog, insulin lispro, in multiple injection therapy may reduce the risk of hypoglycemia in comparison with regular insulin. This effect might be more pronounced in well-controlled patients, since intensive treatment of IDDM increases the rate of severe hypoglycemic events. This study evaluated the effects of insulin lispro on glycemic control and hypoglycemia rates in well-controlled IDDM patients. RESEARCH DESIGN AND METHODS: This was an open, randomized, 6-month crossover study of 199 IDDM patients. Glycemic control was evaluated by HbA1c, home blood glucose measurements, and rate and timing of hypoglycemic events. At the end of the study, patients completed an evaluation form regarding therapy-related quality of life. RESULTS: HbA1c remained constant at approximately 7.3% throughout the study. Meal-related glucose excursions were significantly lower with insulin lispro compared with regular insulin (mean -0.8 +/- 1.7 vs. 1.1 +/- 1.6 mmol/l, P < 0.001), as was the within-day variability (M value 27.7 +/- 19.7 vs. 30.2 +/- 23.1, P = 0.007). The incidence of severe hypoglycemic events (58 vs. 36, P = 0.037) including coma (16 vs. 3, P = 0.004) was significantly lower with insulin lispro than with regular insulin. Patients felt that insulin lispro increased flexibility and freedom of lifestyle. CONCLUSIONS: In well-controlled IDDM patients, insulin lispro is associated with a lower risk of severe hypoglycemia and coma.

    If you would like to obtain the full article, please contact the Diabetes Care publication at the following e-mail address:
    customerservice@diabetes.org

     
         

    Nieuws, Hypo's bij dieren

    Wat is diabetes?, Type 1

    Nieuws, Huidverzorging, winter en diabetes

    Hypoglykemie, George E., Marques J.L., Harris N.D., Macdonald I.A., Hardisty C.A., Heller S.R. : Preservation of physiological responses to hypoglycaemia 2 days after antecedent hypoglycaemia in patients with IDDM.

    Diabetes in het dagelijkse leven, Zwangerschap

    Nieuws, In Cuba worden sinds kort antilichamen aangemaakt, om hepatitis te kunnen behandelen

    Nieuws, Te veel vitamine C niet goed voor het hart van mensen met diabetes.

    Nieuws, Werelddiabetesdag in België

    BD, BD Logo en alle andere merknamen zijn - tenzij anders vermeld - eigendom van Becton, Dickinson and Company. © 2005 BD